Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Newron Pharmaceuticals S.p.A.

Chiesi Farmaceutici S.p.A is involved in the pharmaceutical sector, focusing on respiratory therapies and healthcare research and development. The company provides innovative solutions and collaborates with other organizations for the development of its products.

Chiesi Farmaceutici S.p.A

Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company has built a late-stage pipeline that includes one marketed product and product candidates in clinical development.

Metric
Company Name	Newron Pharmaceuticals S.p.A.	Chiesi Farmaceutici S.p.A
Symbol	NWRN
MSH ID	COM:NEWRON	COM:CHIESI
Market	STOCKS	PRIVATE
Sector		Healthcare & Health Services
Industry		Pharmaceuticals
Country	IT	IT
Stage
Employee Count	23
Website	newron.com	chiesi.com
LinkedIn
Founders

Metric
Market Cap	155.42M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	9.57M
Revenue (LTM)
Revenue (NTM)
Gross Profit	9.57M
EBITDA	-12.50M
Operating Income	-12.28M
Net Income	-17.14M
EPS	-0.96
Diluted EPS	-0.96
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1
Operating Profit Margin	-1.27
EBITDA Margin	-1.31
Net Profit Margin	-1.79
Return on Equity	0.90
Return on Assets	-0.50
Return on Capital Employed	3.80

COM:NEWRON

Newron Pharmaceuticals

Last Close

7.20

25/11 08:59

Market Cap

136.34M

Beta: -

Volume Today

6.96K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.53
P/B Ratio	-10.64
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	26.41
EV Multiple	-7.45

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover	0.35

Metric
Operating Cash Flow	-10.71M
Free Cash Flow	-10.72M
Cash Flow to Debt	-0.21
Operating Cash Flow/Sales	-1.12
Free Cash Flow Yield	-0.07

Metric
Cash & Equivalents	6.69M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	2.74
Debt to Assets	1.23
Current Ratio	5.65
Quick Ratio	3.28

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.08
R&D to Revenue	1.97
SG&A to Revenue	0.58